Cargando…

A single-center single-shot devices experience for pulmonary vein isolation

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Pulmonary vein isolation (PVI) is the gold standard for treatment of atrial fibrillation (AF). Single-shot devices have been introduced to provide a faster and more simplified approach to achieve PVI. We sought to evaluate our sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirstein, B, Heeger, C H, Phan, H L, Eitel, C, Feher, M, Vogler, J, Popescu, S S, Hatahet, S, Keelani, A, Breithaupt, C, Wolf, C, Kuck, K H, Tilz, R R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206927/
http://dx.doi.org/10.1093/europace/euad122.117
Descripción
Sumario:FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Pulmonary vein isolation (PVI) is the gold standard for treatment of atrial fibrillation (AF). Single-shot devices have been introduced to provide a faster and more simplified approach to achieve PVI. We sought to evaluate our single-center experience with different single-shot devices for the treatment of AF. METHODS: Evaluation included 25 propensity score matched patients (age, gender, AF-type, CHADSVAsc score) for each single-shot device (i) Arctic Front 4th generation cryoballon (CB G4), (ii) PolarX cryoballoon, (iii) X3 laserballoon, (iv) single-access pulsed field ablation (PFA) as part of our prospective observational AF registry who underwent first-time ablation for symptomatic AF. The first 20 cases (learning curve) with each technology and those with pre/post mapping were rejected from the analysis. Procedures were performed by the institute´s standard operational procedures. Procedural characteristics and safety data were compared. RESULTS: A total of 100 symptomatic AF patients (66±8 years, 57% paroxysmal AF, 42% female, CHADSVasc Score 1.2±1) underwent first-time PVI with a single-shot device. Acute PVI rates were 96-100%. Treatment with either cryoballoon systems revealed similar procedure characteristics between vendors. Balloon-based procedures were associated with longer procedure times between 54-57 min. Using a single-access PFA approach, procedure (26 [25-30] min) and fluoroscopy times (5 [IQR 5;7] min) were significantly reduced (p<0.001). Significantly smaller amounts of contrast medium were needed in laser and PFA procedures in comparison to both cryoballoons (p<0.001). Adverse event rates did not differ between technologies. Details are given in Table 1-3 and Figure 1. CONCLUSION: In our prospective ablation registry, first-time AF ablation using single-access PFA outperformed other common single-shot devices. Procedure and fluoroscopy times were significantly reduced by approximately 50% in comparison to balloon-based technologies (p<0.001). A comparable safety profile was found between PFA, cryo- and laser energy. [Figure: see text] [Figure: see text]